Medicine by Design is seeking participation from the University of Toronto and the broader Toronto Academic Health Sciences Network (TAHSN) across multiple disciplines (spanning the physical and life sciences, medicine, engineering, and social sciences) and across the academic, private and not-for-profit sectors, in setting new research priorities for Medicine by Design to fulfill the commitments of its new strategic plan.
The Convergent Working Groups will integrate convergent disciplines and experiences that are new to the regenerative medicine community together with those who have been involved with Medicine by Design for many years. Industry partners, regional accelerators and the patients and communities we expect to serve and engage will also be involved.
Successful teams will receive up to $25,000 in Phase 1 funding to address one of the identified research themes (defined below) through a workshop that will produce a position paper with a call to action. Funded groups will then be eligible for Phase 2 funding of an additional $200,000 to implement a 1-year pilot research program.
Under its strategic plan, Medicine by Design has made three commitments to advance its mission to “harness Toronto’s extraordinary expertise across convergent disciplines and institutions to invent, develop, scale and implement living therapies that will transform healthcare for Canada and the world” and to make Toronto “a globally leading ecosystem for regenerative medicine innovation.”
These commitments are:
- Advance transformative research and early-stage translation in regenerative medicine;
- Enable the commercialization of accessible, living therapies at-scale; and
- Prepare health systems, clinics and communities to implement living therapy innovations.
Medicine by Design invites investigators to submit proposals addressing one of the research themes below that aligns with these commitments.